View ValuationAnshan Hifichem 将来の成長Future 基準チェック /06現在、 Anshan Hifichemの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長28.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 30Anshan Hifichem Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Anshan Hifichem Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026New Risk • May 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.1% operating cash flow to total debt). Earnings have declined by 17% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin).お知らせ • Apr 24Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning Chinaお知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.1% net profit margin).New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.1% net profit margin).お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. Independent Director Qi Wang was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Oct 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.1% net profit margin).Reported Earnings • Oct 22Third quarter 2025 earnings released: EPS: CN¥0.05 (vs CN¥0.13 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.05 (down from CN¥0.13 in 3Q 2024). Revenue: CN¥360.1m (down 13% from 3Q 2024). Net income: CN¥20.9m (down 61% from 3Q 2024). Profit margin: 5.8% (down from 13% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025Reported Earnings • Aug 31Second quarter 2025 earnings released: EPS: CN¥0.051 (vs CN¥0.13 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.051 (down from CN¥0.13 in 2Q 2024). Revenue: CN¥394.1m (down 5.3% from 2Q 2024). Net income: CN¥21.7m (down 52% from 2Q 2024). Profit margin: 5.5% (down from 11% in 2Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥13.92, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 39% over the past three years.Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥16.68, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 75% over the past three years.New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Apr 19First quarter 2025 earnings released: EPS: CN¥0.08 (vs CN¥0.05 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.08 (up from CN¥0.05 in 1Q 2024). Revenue: CN¥364.9m (up 13% from 1Q 2024). Net income: CN¥30.8m (up 43% from 1Q 2024). Profit margin: 8.4% (up from 6.7% in 1Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.New Risk • Apr 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (223% cash payout ratio). Large one-off items impacting financial results.お知らせ • Apr 18Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning Chinaお知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025分析記事 • Mar 27At CN¥15.09, Is It Time To Put Anshan Hifichem Co., Ltd. (SZSE:300758) On Your Watch List?Anshan Hifichem Co., Ltd. ( SZSE:300758 ), might not be a large cap stock, but it received a lot of attention from a...Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥15.09, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Chemicals industry in China. Total returns to shareholders of 30% over the past three years.分析記事 • Feb 11Anshan Hifichem (SZSE:300758) Is Reinvesting At Lower Rates Of ReturnWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025分析記事 • Nov 18Is Now The Time To Look At Buying Anshan Hifichem Co., Ltd. (SZSE:300758)?Anshan Hifichem Co., Ltd. ( SZSE:300758 ), is not the largest company out there, but it received a lot of attention...Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2023). Revenue: CN¥415.5m (up 31% from 3Q 2023). Net income: CN¥53.0m (up CN¥45.1m from 3Q 2023). Profit margin: 13% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has remained flat, which means it is well ahead of earnings.分析記事 • Oct 20Anshan Hifichem (SZSE:300758) Might Be Having Difficulty Using Its Capital EffectivelyIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...分析記事 • Oct 01Why Investors Shouldn't Be Surprised By Anshan Hifichem Co., Ltd.'s (SZSE:300758) 27% Share Price SurgeAnshan Hifichem Co., Ltd. ( SZSE:300758 ) shareholders have had their patience rewarded with a 27% share price jump in...New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.8% average weekly change).お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anshan Hifichem Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 31%After last week's 31% share price gain to CN¥13.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 8.4% over the past three years.お知らせ • Sep 21Anshan Hifichem Co., Ltd. Announces 2024 Interim Profit Distribution Plan (A Shares),Payable September 26, 2024Anshan Hifichem Co., Ltd. announced 2024 interim profit distribution plan to be implemented (A shares):Cash dividend/10 shares (tax included): CNY0.50000000. Record date: 25 September 2024, Ex-date: 26 September 2024, Payment date: 26 September 2024.Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.007 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.007 in 2Q 2023). Revenue: CN¥416.2m (up 35% from 2Q 2023). Net income: CN¥45.6m (up CN¥42.6m from 2Q 2023). Profit margin: 11% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.分析記事 • Jul 26Anshan Hifichem (SZSE:300758) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Jun 29Anshan Hifichem Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024Anshan Hifichem Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024分析記事 • May 27There's Reason For Concern Over Anshan Hifichem Co., Ltd.'s (SZSE:300758) Massive 30% Price JumpDespite an already strong run, Anshan Hifichem Co., Ltd. ( SZSE:300758 ) shares have been powering on, with a gain of...分析記事 • May 06Anshan Hifichem (SZSE:300758) Could Be Struggling To Allocate CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Reported Earnings • Apr 16First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.05 (up from CN¥0.04 loss in 1Q 2023). Revenue: CN¥322.5m (up 22% from 1Q 2023). Net income: CN¥21.6m (up CN¥36.4m from 1Q 2023). Profit margin: 6.7% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Large one-off items impacting financial results.お知らせ • Mar 30Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024Anshan Hifichem Co., Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024分析記事 • Feb 28With Anshan Hifichem Co., Ltd. (SZSE:300758) It Looks Like You'll Get What You Pay ForAnshan Hifichem Co., Ltd.'s ( SZSE:300758 ) price-to-sales (or "P/S") ratio of 2.8x may not look like an appealing...お知らせ • Feb 09Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning ChinaNew Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results.Reported Earnings • Feb 07Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: CN¥0.03 (up from CN¥0.01 loss in FY 2022). Revenue: CN¥1.22b (flat on FY 2022). Net income: CN¥11.0m (up CN¥13.8m from FY 2022). Profit margin: 0.9% (up from net loss in FY 2022). Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 40%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.New Risk • Feb 07New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Dec 29Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2023 results on Feb 29, 2024New Risk • Dec 22New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.021 (up from CN¥0.009 loss in 3Q 2022). Revenue: CN¥317.7m (up 7.1% from 3Q 2022). Net income: CN¥7.96m (up CN¥10.6m from 3Q 2022). Profit margin: 2.5% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Anshan Hifichem Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.007 (up from CN¥0.002 in 2Q 2022). Revenue: CN¥308.0m (flat on 2Q 2022). Net income: CN¥2.96m (up 188% from 2Q 2022). Profit margin: 1.0% (up from 0.3% in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 26First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)First quarter 2023 results: CN¥0.04 loss per share (down from CN¥0.06 profit in 1Q 2022). Revenue: CN¥263.6m (down 18% from 1Q 2022). Net loss: CN¥14.8m (down 160% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.Board Change • Nov 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Deputy GM & Non-Independent Director Zhi Qiao was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 26Third quarter 2022 earnings released: CN¥0.009 loss per share (vs CN¥0.094 profit in 3Q 2021)Third quarter 2022 results: CN¥0.009 loss per share (down from CN¥0.094 profit in 3Q 2021). Revenue: CN¥296.5m (down 8.3% from 3Q 2021). Net loss: CN¥2.59m (down 107% from profit in 3Q 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.お知らせ • Oct 18Anshan Hifichem Co., Ltd. Announces Directorate ChangesAnshan Hifichem Co., Ltd. announced that at the Extraordinary General Meeting of 2022 held on 14 October 2022 approved Resignation and by-election of independent directors namely Wang Qi and Wang Yonghua.Valuation Update With 7 Day Price Move • Sep 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to CN¥13.50, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Chemicals industry in China. Total returns to shareholders of 36% over the past three years.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.18 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.002 (down from CN¥0.18 in 2Q 2021). Revenue: CN¥310.0m (up 3.0% from 2Q 2021). Net income: CN¥1.03m (down 98% from 2Q 2021). Profit margin: 0.3% (down from 22% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 41%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 29% share price gain to CN¥16.08, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 85% over the past three years.Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to CN¥12.31, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 18% over the past three years.お知らせ • May 20Anshan Hifichem Co., Ltd. Approves 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on May 26, 2022Anshan Hifichem Co., Ltd. approved 2021 final profit distribution plan to be implemented (A shares), payable on May 26, 2022. The company announced Cash dividend/10 shares (tax included) of CNY 2.00000000. The Ex-dividend date is May 26, 2022 and record date is May 25, 2022.お知らせ • May 19Anshan Hifichem Co., Ltd. Approves Cash DividendAnshan Hifichem Co., Ltd. at the AGM held on 16 May 2022, approved cash dividend (tax included) of CNY 2.00000000 per 10 shares.Reported Earnings • Apr 27First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: EPS: CN¥0.06 (down from CN¥0.15 in 1Q 2021). Revenue: CN¥323.2m (up 4.5% from 1Q 2021). Net income: CN¥24.7m (down 49% from 1Q 2021). Profit margin: 7.6% (down from 16% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) missed analyst estimates by 5.2%. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Deputy GM & Non-Independent Director Zhi Qiao was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 26Anshan Hifichem Co., Ltd. Proposes Final Dividend for the Year 2021Anshan Hifichem Co., Ltd. proposed final cash dividend of CNY 2.00000000 per 10 shares (tax included) for the year 2021.Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.094 (vs CN¥0.12 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥323.4m (up 20% from 3Q 2020). Net income: CN¥36.9m (down 11% from 3Q 2020). Profit margin: 11% (down from 16% in 3Q 2020). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 38% share price decline to CN¥14.59, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 51% over the past year.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥24.70, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Chemicals industry in China. Negligible returns to shareholders over past year.Reported Earnings • Aug 26Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.28 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥301.1m (up 21% from 2Q 2020). Net income: CN¥64.9m (up 19% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020).Valuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥25.44, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 22% over the past year.お知らせ • May 26+ 1 more updateAnshan Hifichem Co., Ltd. (SZSE:300758) agreed to acquire additional 29% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. from Chen Jianxin for approximately CNY 150 million.Anshan Hifichem Co., Ltd. (SZSE:300758) agreed to acquire additional 29% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. from Chen Jianxin for approximately CNY 150 million on May 24, 2021. As per terms of transaction first part of consideration is of CNY 5.8 million for this equity transfer within 3 working days after the signing of this agreement, Second part of consideration is of CNY 8.7 million for this equity transfer before June 18, 2021. After the transaction is completed, both parties agree that the target company will operate in accordance with the current board of directors and organizational structure. Post completion, Anshan Hifichem Co., Ltd. will hold 80% stake and Chen Jianxin will hold 20% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. As on March 31, 2021, Anshan Hifichem Co., Ltd. reported total assets of approximately CNY 410 million, net assets of approximately CNY 240 million, operating income of CNY 97 million, net profit of CNY 1.2 billion. Transaction is subject to shareholder approval and is approved by the Board of Anshan Hifichem Co., Ltd.Reported Earnings • Apr 16Full year 2020 earnings released: EPS CN¥0.91 (vs CN¥0.59 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.01b (up 45% from FY 2019). Net income: CN¥175.5m (up 62% from FY 2019). Profit margin: 17% (up from 16% in FY 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Jan 11New 90-day low: CN¥21.86The company is down 17% from its price of CN¥26.29 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥5.14 per share.Is New 90 Day High Low • Dec 18New 90-day low: CN¥23.42The company is down 14% from its price of CN¥27.14 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.46 per share.Valuation Update With 7 Day Price Move • Nov 18Market bids up stock over the past weekAfter last week's 22% share price gain to CN¥31.60, the stock is trading at a trailing P/E ratio of 43.2x, up from the previous P/E ratio of 35.6x. This compares to an average P/E of 38x in the Chemicals industry in China. Total returns to shareholders over the past year are 79%.Is New 90 Day High Low • Nov 12New 90-day low: CN¥23.45The company is down 27% from its price of CN¥32.00 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period.Reported Earnings • Oct 28Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 18% from the prior year. Total revenue was CN¥876.9m over the last 12 months, up 33% from the prior year.Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 19% share price gain to CN¥29.66, the stock is trading at a trailing P/E ratio of 39.9x, up from the previous P/E ratio of 33.4x. This compares to an average P/E of 40x in the Chemicals industry in China. Total returns to shareholders over the past year are 66%.お知らせ • Aug 06Anshan Hifichem Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020Anshan Hifichem Co., Ltd. announced that they will report first half, 2020 results on Aug 25, 2020 このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Anshan Hifichem は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測SZSE:300758 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261,53146-4094N/A12/31/20251,49561-9864N/A9/30/20251,53378-9749N/A6/30/20251,588110-7862N/A3/31/20251,61013418103N/A12/31/20241,56812558133N/A9/30/20241,48313532130N/A6/30/20241,38590-3686N/A3/31/20241,27747-9348N/A12/31/20231,21811-1642N/A9/30/20231,168-30-17243N/A6/30/20231,147-40-16356N/A3/31/20231,149-42-80122N/A1/1/20231,209-3-9992N/A9/30/20221,34353-40107N/A6/30/20221,37093-38118N/A3/31/20221,361157-63107N/A1/1/20221,347180-1161N/A9/30/20211,248192-25143N/A6/30/20211,193197-39119N/A3/31/20211,142187-26123N/A12/31/20201,008175-14193N/A9/30/2020877141-18184N/A6/30/2020774142-19562N/A3/31/2020724130-23815N/A12/31/2019695108N/A49N/A9/30/2019661120N/A47N/A6/30/2019664111N/A85N/A3/31/2019628100N/A87N/A12/31/2018611105N/A68N/A9/30/2018606115N/A63N/A6/30/2018583110N/A76N/A3/31/2018550101N/A48N/A12/31/2017553103N/A72N/A9/30/2017525100N/A61N/A6/30/201749896N/A51N/A3/31/201747086N/A62N/A12/31/201644276N/A73N/A9/30/201641960N/AN/AN/A6/30/201639644N/A29N/A3/31/201638341N/A30N/A12/31/201537039N/A32N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 300758の予測収益成長が 貯蓄率 ( 2.4% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 300758の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 300758の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 300758の収益がCN市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 300758の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 300758の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 00:40終値2026/08/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anshan Hifichem Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Nai Di ZhaoEverbright Securities Co. Ltd.Wei LiuHaitong International Research Limited
お知らせ • Jun 30Anshan Hifichem Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026Anshan Hifichem Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026
New Risk • May 26New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.5% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (8.1% operating cash flow to total debt). Earnings have declined by 17% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin).
お知らせ • Apr 24Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026Anshan Hifichem Co., Ltd., Annual General Meeting, May 15, 2026, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2026 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.1% net profit margin).
New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.1% net profit margin).
お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026
Board Change • Nov 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. Independent Director Qi Wang was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Oct 24New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (4.5% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.1% net profit margin).
Reported Earnings • Oct 22Third quarter 2025 earnings released: EPS: CN¥0.05 (vs CN¥0.13 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.05 (down from CN¥0.13 in 3Q 2024). Revenue: CN¥360.1m (down 13% from 3Q 2024). Net income: CN¥20.9m (down 61% from 3Q 2024). Profit margin: 5.8% (down from 13% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2025 Results on Oct 22, 2025Anshan Hifichem Co., Ltd. announced that they will report Q3, 2025 results on Oct 22, 2025
Reported Earnings • Aug 31Second quarter 2025 earnings released: EPS: CN¥0.051 (vs CN¥0.13 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.051 (down from CN¥0.13 in 2Q 2024). Revenue: CN¥394.1m (down 5.3% from 2Q 2024). Net income: CN¥21.7m (down 52% from 2Q 2024). Profit margin: 5.5% (down from 11% in 2Q 2024). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 30New major risk - Revenue and earnings growthEarnings have declined by 23% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Jul 02Anshan Hifichem Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025Anshan Hifichem Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to CN¥13.92, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 39% over the past three years.
Valuation Update With 7 Day Price Move • May 08Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CN¥16.68, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 20x in the Chemicals industry in China. Total returns to shareholders of 75% over the past three years.
New Risk • May 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Apr 19First quarter 2025 earnings released: EPS: CN¥0.08 (vs CN¥0.05 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.08 (up from CN¥0.05 in 1Q 2024). Revenue: CN¥364.9m (up 13% from 1Q 2024). Net income: CN¥30.8m (up 43% from 1Q 2024). Profit margin: 8.4% (up from 6.7% in 1Q 2024). Revenue is forecast to grow 28% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
New Risk • Apr 19New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 28% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (223% cash payout ratio). Large one-off items impacting financial results.
お知らせ • Apr 18Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025Anshan Hifichem Co., Ltd., Annual General Meeting, May 09, 2025, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
お知らせ • Mar 31Anshan Hifichem Co., Ltd. to Report Q1, 2025 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report Q1, 2025 results on Apr 18, 2025
分析記事 • Mar 27At CN¥15.09, Is It Time To Put Anshan Hifichem Co., Ltd. (SZSE:300758) On Your Watch List?Anshan Hifichem Co., Ltd. ( SZSE:300758 ), might not be a large cap stock, but it received a lot of attention from a...
Valuation Update With 7 Day Price Move • Mar 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥15.09, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Chemicals industry in China. Total returns to shareholders of 30% over the past three years.
分析記事 • Feb 11Anshan Hifichem (SZSE:300758) Is Reinvesting At Lower Rates Of ReturnWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically...
お知らせ • Dec 31Anshan Hifichem Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025
分析記事 • Nov 18Is Now The Time To Look At Buying Anshan Hifichem Co., Ltd. (SZSE:300758)?Anshan Hifichem Co., Ltd. ( SZSE:300758 ), is not the largest company out there, but it received a lot of attention...
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.021 in 3Q 2023). Revenue: CN¥415.5m (up 31% from 3Q 2023). Net income: CN¥53.0m (up CN¥45.1m from 3Q 2023). Profit margin: 13% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
分析記事 • Oct 20Anshan Hifichem (SZSE:300758) Might Be Having Difficulty Using Its Capital EffectivelyIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
分析記事 • Oct 01Why Investors Shouldn't Be Surprised By Anshan Hifichem Co., Ltd.'s (SZSE:300758) 27% Share Price SurgeAnshan Hifichem Co., Ltd. ( SZSE:300758 ) shareholders have had their patience rewarded with a 27% share price jump in...
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.8% average weekly change).
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024Anshan Hifichem Co., Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 31%After last week's 31% share price gain to CN¥13.06, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 8.4% over the past three years.
お知らせ • Sep 21Anshan Hifichem Co., Ltd. Announces 2024 Interim Profit Distribution Plan (A Shares),Payable September 26, 2024Anshan Hifichem Co., Ltd. announced 2024 interim profit distribution plan to be implemented (A shares):Cash dividend/10 shares (tax included): CNY0.50000000. Record date: 25 September 2024, Ex-date: 26 September 2024, Payment date: 26 September 2024.
Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.007 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.007 in 2Q 2023). Revenue: CN¥416.2m (up 35% from 2Q 2023). Net income: CN¥45.6m (up CN¥42.6m from 2Q 2023). Profit margin: 11% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance.
分析記事 • Jul 26Anshan Hifichem (SZSE:300758) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Jun 29Anshan Hifichem Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024Anshan Hifichem Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024
分析記事 • May 27There's Reason For Concern Over Anshan Hifichem Co., Ltd.'s (SZSE:300758) Massive 30% Price JumpDespite an already strong run, Anshan Hifichem Co., Ltd. ( SZSE:300758 ) shares have been powering on, with a gain of...
分析記事 • May 06Anshan Hifichem (SZSE:300758) Could Be Struggling To Allocate CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Reported Earnings • Apr 16First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.04 loss in 1Q 2023)First quarter 2024 results: EPS: CN¥0.05 (up from CN¥0.04 loss in 1Q 2023). Revenue: CN¥322.5m (up 22% from 1Q 2023). Net income: CN¥21.6m (up CN¥36.4m from 1Q 2023). Profit margin: 6.7% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Chinese stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Large one-off items impacting financial results.
お知らせ • Mar 30Anshan Hifichem Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024Anshan Hifichem Co., Ltd. announced that they will report Q1, 2024 results on Apr 24, 2024
分析記事 • Feb 28With Anshan Hifichem Co., Ltd. (SZSE:300758) It Looks Like You'll Get What You Pay ForAnshan Hifichem Co., Ltd.'s ( SZSE:300758 ) price-to-sales (or "P/S") ratio of 2.8x may not look like an appealing...
お知らせ • Feb 09Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024Anshan Hifichem Co., Ltd., Annual General Meeting, Mar 01, 2024, at 13:00 China Standard Time. Location: No. 8, Yihao Road, Teng'ao Economic Development Zone, Haicheng, Anshan, Liaoning China
New Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Large one-off items impacting financial results.
Reported Earnings • Feb 07Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: EPS: CN¥0.03 (up from CN¥0.01 loss in FY 2022). Revenue: CN¥1.22b (flat on FY 2022). Net income: CN¥11.0m (up CN¥13.8m from FY 2022). Profit margin: 0.9% (up from net loss in FY 2022). Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 40%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
New Risk • Feb 07New major risk - Revenue and earnings growthEarnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Dec 29Anshan Hifichem Co., Ltd. to Report Fiscal Year 2023 Results on Feb 29, 2024Anshan Hifichem Co., Ltd. announced that they will report fiscal year 2023 results on Feb 29, 2024
New Risk • Dec 22New major risk - Revenue and earnings growthEarnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
Reported Earnings • Oct 27Third quarter 2023 earnings released: EPS: CN¥0.021 (vs CN¥0.009 loss in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.021 (up from CN¥0.009 loss in 3Q 2022). Revenue: CN¥317.7m (up 7.1% from 3Q 2022). Net income: CN¥7.96m (up CN¥10.6m from 3Q 2022). Profit margin: 2.5% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
New Risk • Oct 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
お知らせ • Sep 30Anshan Hifichem Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023Anshan Hifichem Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.007 (vs CN¥0.002 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.007 (up from CN¥0.002 in 2Q 2022). Revenue: CN¥308.0m (flat on 2Q 2022). Net income: CN¥2.96m (up 188% from 2Q 2022). Profit margin: 1.0% (up from 0.3% in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 26First quarter 2023 earnings released: CN¥0.04 loss per share (vs CN¥0.06 profit in 1Q 2022)First quarter 2023 results: CN¥0.04 loss per share (down from CN¥0.06 profit in 1Q 2022). Revenue: CN¥263.6m (down 18% from 1Q 2022). Net loss: CN¥14.8m (down 160% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
Board Change • Nov 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Deputy GM & Non-Independent Director Zhi Qiao was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 26Third quarter 2022 earnings released: CN¥0.009 loss per share (vs CN¥0.094 profit in 3Q 2021)Third quarter 2022 results: CN¥0.009 loss per share (down from CN¥0.094 profit in 3Q 2021). Revenue: CN¥296.5m (down 8.3% from 3Q 2021). Net loss: CN¥2.59m (down 107% from profit in 3Q 2021). Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
お知らせ • Oct 18Anshan Hifichem Co., Ltd. Announces Directorate ChangesAnshan Hifichem Co., Ltd. announced that at the Extraordinary General Meeting of 2022 held on 14 October 2022 approved Resignation and by-election of independent directors namely Wang Qi and Wang Yonghua.
Valuation Update With 7 Day Price Move • Sep 21Investor sentiment improved over the past weekAfter last week's 22% share price gain to CN¥13.50, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Chemicals industry in China. Total returns to shareholders of 36% over the past three years.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.18 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.002 (down from CN¥0.18 in 2Q 2021). Revenue: CN¥310.0m (up 3.0% from 2Q 2021). Net income: CN¥1.03m (down 98% from 2Q 2021). Profit margin: 0.3% (down from 22% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 41%, compared to a 42% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Aug 12Investor sentiment improved over the past weekAfter last week's 29% share price gain to CN¥16.08, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 85% over the past three years.
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improved over the past weekAfter last week's 22% share price gain to CN¥12.31, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 18% over the past three years.
お知らせ • May 20Anshan Hifichem Co., Ltd. Approves 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on May 26, 2022Anshan Hifichem Co., Ltd. approved 2021 final profit distribution plan to be implemented (A shares), payable on May 26, 2022. The company announced Cash dividend/10 shares (tax included) of CNY 2.00000000. The Ex-dividend date is May 26, 2022 and record date is May 25, 2022.
お知らせ • May 19Anshan Hifichem Co., Ltd. Approves Cash DividendAnshan Hifichem Co., Ltd. at the AGM held on 16 May 2022, approved cash dividend (tax included) of CNY 2.00000000 per 10 shares.
Reported Earnings • Apr 27First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2022 results: EPS: CN¥0.06 (down from CN¥0.15 in 1Q 2021). Revenue: CN¥323.2m (up 4.5% from 1Q 2021). Net income: CN¥24.7m (down 49% from 1Q 2021). Profit margin: 7.6% (down from 16% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.2%. Earnings per share (EPS) missed analyst estimates by 5.2%. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Deputy GM & Non-Independent Director Zhi Qiao was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 26Anshan Hifichem Co., Ltd. Proposes Final Dividend for the Year 2021Anshan Hifichem Co., Ltd. proposed final cash dividend of CNY 2.00000000 per 10 shares (tax included) for the year 2021.
Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.094 (vs CN¥0.12 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥323.4m (up 20% from 3Q 2020). Net income: CN¥36.9m (down 11% from 3Q 2020). Profit margin: 11% (down from 16% in 3Q 2020). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment deteriorated over the past weekAfter last week's 38% share price decline to CN¥14.59, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 51% over the past year.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to CN¥24.70, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 20x in the Chemicals industry in China. Negligible returns to shareholders over past year.
Reported Earnings • Aug 26Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.28 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥301.1m (up 21% from 2Q 2020). Net income: CN¥64.9m (up 19% from 2Q 2020). Profit margin: 22% (in line with 2Q 2020).
Valuation Update With 7 Day Price Move • Aug 17Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥25.44, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 20x in the Chemicals industry in China. Total loss to shareholders of 22% over the past year.
お知らせ • May 26+ 1 more updateAnshan Hifichem Co., Ltd. (SZSE:300758) agreed to acquire additional 29% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. from Chen Jianxin for approximately CNY 150 million.Anshan Hifichem Co., Ltd. (SZSE:300758) agreed to acquire additional 29% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. from Chen Jianxin for approximately CNY 150 million on May 24, 2021. As per terms of transaction first part of consideration is of CNY 5.8 million for this equity transfer within 3 working days after the signing of this agreement, Second part of consideration is of CNY 8.7 million for this equity transfer before June 18, 2021. After the transaction is completed, both parties agree that the target company will operate in accordance with the current board of directors and organizational structure. Post completion, Anshan Hifichem Co., Ltd. will hold 80% stake and Chen Jianxin will hold 20% stake in Shaoxing Shangyu Xinli Chemical Industry Co., Ltd. As on March 31, 2021, Anshan Hifichem Co., Ltd. reported total assets of approximately CNY 410 million, net assets of approximately CNY 240 million, operating income of CNY 97 million, net profit of CNY 1.2 billion. Transaction is subject to shareholder approval and is approved by the Board of Anshan Hifichem Co., Ltd.
Reported Earnings • Apr 16Full year 2020 earnings released: EPS CN¥0.91 (vs CN¥0.59 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.01b (up 45% from FY 2019). Net income: CN¥175.5m (up 62% from FY 2019). Profit margin: 17% (up from 16% in FY 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Jan 11New 90-day low: CN¥21.86The company is down 17% from its price of CN¥26.29 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥5.14 per share.
Is New 90 Day High Low • Dec 18New 90-day low: CN¥23.42The company is down 14% from its price of CN¥27.14 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.46 per share.
Valuation Update With 7 Day Price Move • Nov 18Market bids up stock over the past weekAfter last week's 22% share price gain to CN¥31.60, the stock is trading at a trailing P/E ratio of 43.2x, up from the previous P/E ratio of 35.6x. This compares to an average P/E of 38x in the Chemicals industry in China. Total returns to shareholders over the past year are 79%.
Is New 90 Day High Low • Nov 12New 90-day low: CN¥23.45The company is down 27% from its price of CN¥32.00 on 14 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period.
Reported Earnings • Oct 28Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥141.1m, up 18% from the prior year. Total revenue was CN¥876.9m over the last 12 months, up 33% from the prior year.
Valuation Update With 7 Day Price Move • Oct 15Market bids up stock over the past weekAfter last week's 19% share price gain to CN¥29.66, the stock is trading at a trailing P/E ratio of 39.9x, up from the previous P/E ratio of 33.4x. This compares to an average P/E of 40x in the Chemicals industry in China. Total returns to shareholders over the past year are 66%.
お知らせ • Aug 06Anshan Hifichem Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020Anshan Hifichem Co., Ltd. announced that they will report first half, 2020 results on Aug 25, 2020